Abstract
BackgroundHead and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide. Recently, the introduction of immunotherapy has improved outcomes in the frontline treatment of recurrent/metastatic (r/m) HNSCC,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
